FDA approval for Novartis' melanoma combo
admin 1st May 2018 Uncategorised 0Tafinlar/Mekinist combo is the first oral targeted adjuvant combination therapy to demonstrate significant clinical benefit in patients with a BRAF V600 mutation
More: FDA approval for Novartis' melanoma combo
Source: News